StockData
Valion Bio, Inc. logo

Valion Bio, Inc. (VBIO) stock

VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.54+0.01 (+2.72%)

Close on Nov 17, 2026Market cap $2.26MP/E –Yield –

Valion Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Valion Bio's operating income for the twelve months ending Jun 30, 2026 was -$16.52M. For fiscal 2025 it was -$7.90M. The highest annual figure on record is -$4.48M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.90M–
FY2024Dec 31, 2024-$4.48M–
FY2023Dec 31, 2023-$8.25M–
FY2022Dec 31, 2022-$10.10M–
FY2021Dec 31, 2021-$5.63M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.42M–
Q1 FY2026Mar 31, 2026-$5.63M–
Q4 FY2025Dec 31, 2025-$1.98M–
Q3 FY2025Sep 30, 2025-$2.48M–
Q2 FY2025Jun 30, 2025-$1.68M–
Q1 FY2025Mar 31, 2025-$1.38M–
Q4 FY2024Dec 31, 2024-$298.00K–
Q3 FY2024Sep 30, 2024-$1.43M–
Q2 FY2024Jun 30, 2024-$1.27M–
Q1 FY2024Mar 31, 2024-$1.48M–
Q4 FY2023Dec 31, 2023-$2.24M–
Q3 FY2023Sep 30, 2023-$1.76M–
Q2 FY2023Jun 30, 2023-$2.13M–
Q1 FY2023Mar 31, 2023-$2.12M–
Q4 FY2022Dec 31, 2022-$2.26M–
Q3 FY2022Sep 30, 2022-$2.58M–
Q2 FY2022Jun 30, 2022-$3.02M–
Q1 FY2022Mar 31, 2022-$2.24M–
Q4 FY2021Dec 31, 2021-$2.29M–
Q3 FY2021Sep 30, 2021-$1.23M–
Q2 FY2021Jun 30, 2021-$1.06M–
Q1 FY2021Mar 31, 2021-$1.06M–

More Valion Bio figures

See a number that looks wrong?